Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SX-682 and Atezolizumab in Advanced NSCLC
NCT07322341Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Oct 2026
- Primary completion
- Nov 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SX-682 in non-small cell lung cancer (NSCLC), sponsored by University of Washington. Started Oct 2026; status: recruiting.
02
Drugs
SX-682
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07322341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07322341.